A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
Latest Information Update: 06 Mar 2025
At a glance
- Drugs KT 474 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms ADVANTA
- Sponsors Sanofi
- 01 Nov 2024 Planned number of patients changed from 115 to 200.
- 01 Nov 2024 Planned End Date changed from 14 Feb 2025 to 18 Aug 2026.
- 01 Nov 2024 Planned primary completion date changed from 17 Jan 2025 to 21 Jul 2026.